Updated Data Continue to Showcase Efficacy of Larotrectinib, Entrectinib in NSCLC .

Alexander Drilon, MD

Larotrectinib (Vitrakvi) showcased an overall response rate (ORR) of 71% in patients with non–small cell lung cancer (NSCLC) harboring NTRKgene fusions, according to findings presented at the 2019 European Lung Cancer Congress (ELCC).1

The subset data were from the LOXO-TRK-14001 (NCT02122913) and NAVIGATE (NCT02576431) studies, which contributed to the FDA’s accelerated approval of the TRK inhibitor in November 2018. The agent is indicated for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative therapies or that have progressed following treatment. ...